Literature DB >> 19178120

The applicability and generalizability of findings from clinical trials for health-policy decisions.

Nick Freemantle1, Franz Hessel.   

Abstract

Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with clinical practice. The intention-to-treat principle will lead to dilution in the treatment effect, while the selective recruitment of adherent and motivated subjects may lead to enhanced treatment effect estimates. Observational data, on the other hand, may reflect clinical practice but cannot provide unbiased estimates of treatment effect. Health policy may be informed by the combination of randomized and observational data in decision-analytic models.

Mesh:

Year:  2009        PMID: 19178120     DOI: 10.2165/00019053-200927010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

Review 1.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.

Authors:  J Geddes; N Freemantle; P Harrison; P Bebbington
Journal:  BMJ       Date:  2000-12-02

Review 2.  Generalisability in economic evaluation studies in healthcare: a review and case studies.

Authors:  M J Sculpher; F S Pang; A Manca; M F Drummond; S Golder; H Urdahl; L M Davies; A Eastwood
Journal:  Health Technol Assess       Date:  2004-12       Impact factor: 4.014

3.  Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; R J Heine; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2006-08       Impact factor: 10.122

4.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

5.  The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial.

Authors:  S Del Prato; L Blonde; L Martinez; B Göke; V Woo; A Millward; R Gomis; B Canovatchel; T Strack; D Lawrence; N Freemantle
Journal:  Diabet Med       Date:  2008-04-23       Impact factor: 4.359

6.  Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study.

Authors:  Melanie J Calvert; Richard J McManus; Nick Freemantle
Journal:  Br J Gen Pract       Date:  2007-06       Impact factor: 5.386

  6 in total
  4 in total

Review 1.  Frequency of treatment-effect modification affecting indirect comparisons: a systematic review.

Authors:  Michael Coory; Susan Jordan
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Authors:  Christopher Carswell; Amanda Wheeler; Jane Vanderpyl; Elizabeth Robinson
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding?

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.558

4.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.